A multidisciplinary team of scientists led by Carlo Ballatore, Ph.D., at University of California San Diego and Kurt Brunden, Ph.
D., at the University of Pennsylvania has been awarded a $6.9 million grant from the National Institute on Aging (NIA) to prepare a potential disease-modifying Alzheimer's treatment for future clinical trials.
In a recently published study about the new compound, called CNDR-51997, the team found it was effective in restoring brain health in mouse models of Alzheimer's disease. CNDR-51997 was identified through a joint drug discovery program at Penn and UC San Diego that was supported by grants from the NIA. The new grant will help the researchers demonstrate the drug's safety in formal studies required by the U.
S. Food and Drug Administration (FDA) prior to the initiation of human testing. By the end of the three-year grant period, the researchers hope to submit an Investigational New Drug (IND) application to the FDA that, if approved, would allow for Phase 1 clinical studies.
Alzheimer's is a devastating disease with very few treatment options, so we are eager to advance CNDR-51997 through the drug development process. This compound has been designed to combat tau-mediated neurodegeneration and our preclinical data suggest that it could be beneficial for the treatment of Alzheimer's and related dementias." Carlo Ballatore, Ph.
D., Professor at UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences Alzheimer's disease is characterized b.